Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment

Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells

(2014) You Zhou et al.   BIOMEDICINE & PHARMACOTHERAPY

Sin3a-associated Hdac1 and Hdac2 are essential for hematopoietic stem cell homeostasis and contribute differentially to hematopoiesis

(2014) M. R. Heideman et al.   HAEMATOLOGICA

Tackling the cancer stem cells — what challenges do they pose?

(2014) Diwakar R. Pattabiraman et al.   NATURE REVIEWS DRUG DISCOVERY

The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts

(2013) Richard D.W. Kelly et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability

(2013) Benjamin E. L. Lauffer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mutation signature of adenoid cystic carcinoma: evidence for transcriptional and epigenetic reprogramming

(2013) Henry F. Frierson et al.   JOURNAL OF CLINICAL INVESTIGATION

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

(2013) Denise A. Yardley et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes

(2013) Thomas Prebet et al.   LEUKEMIA RESEARCH

The mutational landscape of adenoid cystic carcinoma

(2013) Allen S Ho et al.   NATURE GENETICS

The future of epigenetic therapy in solid tumours—lessons from the past

(2013) Nilofer Azad et al.   Nature Reviews Clinical Oncology

Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine

(2013) Yushi Yao et al.   PLoS One

CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells

(2012) Ke Gong et al.   BIOCHEMICAL JOURNAL

Cancer Genetics and Epigenetics: Two Sides of the Same Coin?

(2012) Jueng Soo You et al.   CANCER CELL

Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

(2012) Mei Dong et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Cancer Epigenetics: From Mechanism to Therapy

(2012) Mark A. Dawson et al.   CELL

Molecular Pathways: Old Drugs Define New Pathways: Non-Histone Acetylation at the Crossroads of the DNA Damage Response and Autophagy

(2012) O. A. Botrugno et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

(2012) Samir E. Witta et al.   JOURNAL OF CLINICAL ONCOLOGY

Histone Deacetylases 6 and 9 and Sirtuin-1 Control Foxp3+ Regulatory T Cell Function Through Shared and Isoform-Specific Mechanisms

(2012) U. H. Beier et al.   Science Signaling

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy

(2012) Li Shen et al.   OncoImmunology

Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity to Chemoradiotherapy in Non-Small Cell Lung Cancer

(2011) Yasushi Shintani et al.   ANNALS OF THORACIC SURGERY

Peripheral T-cell lymphoma

(2011) F. M. Foss et al.   BLOOD

Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity

(2011) Zhi-Qiang Ning et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

HDACs link the DNA damage response, processing of double-strand breaks and autophagy

(2011) Thomas Robert et al.   NATURE

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

(2011) Marcus Bantscheff et al.   NATURE BIOTECHNOLOGY

Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer

(2011) R. A. Juergens et al.   Cancer Discovery

Sp1/NFκB/HDAC/miR-29b Regulatory Network in KIT-Driven Myeloid Leukemia

(2010) Shujun Liu et al.   CANCER CELL

Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate

(2010) Bin Zhang et al.   CANCER CELL

Drugging Drug Resistance

(2010) Jan-Hermen Dannenberg et al.   CELL

Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis

(2010) Roel H Wilting et al.   EMBO JOURNAL

Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

(2010) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Using histone deacetylase inhibitors to enhance Foxp3+ regulatory T-cell function and induce allograft tolerance

(2009) Liqing Wang et al.   IMMUNOLOGY AND CELL BIOLOGY

Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells

(2008) Mareike Schmudde et al.   CANCER LETTERS

HDAC family: What are the cancer relevant targets?

(2008) Olaf Witt et al.   CANCER LETTERS

Pimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases

(2008) C. James Chou et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

(2008)   JOURNAL OF CLINICAL ONCOLOGY

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

(2008) Michael Haberland et al.   NATURE REVIEWS GENETICS